REMARKS

Objections to the Specification

The Examiner objects to the title and the Abstract of the Disclosure as not adequately describing the claimed invention. As proposed by the Examiner, Applicants now amend the title and the abstract to each include a reference to plant cells and plants expressing chimeric isoprenoid synthases. No new matter has been added by this amendment.

The Examiner also objects to the informal arrangement of the specification. This objection is rendered moot by the amendments to the specification.

Rejection of Claims 1-15 for Obviousness-type Double Patenting

Claims 1-15 are rejected under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 9-12 of U.S. Patent No. 5,824,774 and claims 1-10 of U.S. Patent No. 6,072,045. To overcome this rejection, Applicants submit herewith a timely terminal disclaimer in compliance with 37 C.F.R. § 1.321(c), signed by the assignee in compliance with 37 C.F.R. § 3.73(b).

Enclosed is a petition and a check in the amount of \$920.00 to extend the period for replying for three months, to and including December 11, 2001. If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 11 Deceber 2001

Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200

Facsimile: 617-428-7045

256 40 35,238

Paul T. Clark Reg. No. 30,162

21559
PATENT:TRADEMARK OFFICE